Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pulmonary Enteric Adenocarcinoma

Pulmonary enteric adeno-carcinoma (PEAC) is a rare type of non-small cell lung cancer (NSCLC), for which no established standard treatment exists. Combination therapy with the anti-programmed cell death protein 1 antibody pembrolizumab and platinum-containing chemotherapy is the standard treatment f...

Full description

Saved in:
Bibliographic Details
Published inCancer diagnosis & prognosis Vol. 2; no. 2; pp. 253 - 257
Main Authors Teranishi, Shuhei, Sugimoto, Chihiro, Nagayama, Hirokazu, Segawa, Wataru, Miyasaka, Atsushi, Hiro, Shuntaro, Maeda, Chihiro, Tamura, Hironori, Masumoto, Nami, Nagahara, Yoshinori, Hirama, Nobuyuki, Kobayashi, Nobuaki, Yamamoto, Masaki, Kudo, Makoto, Kaneko, Takeshi
Format Journal Article
LanguageEnglish
Published Greece International Institute of Anticancer Research 03.03.2022
Subjects
Case Report
pembrolizumab
Pulmonary enteric adenocarcinoma
immune checkpoint inhibitor
combination chemotherapy
Online AccessGet full text

Cover

More Information
Summary:Pulmonary enteric adeno-carcinoma (PEAC) is a rare type of non-small cell lung cancer (NSCLC), for which no established standard treatment exists. Combination therapy with the anti-programmed cell death protein 1 antibody pembrolizumab and platinum-containing chemotherapy is the standard treatment for NSCLC patients, but its effectiveness in PEAC is uncertain. We present a 68-year-old man with chemotherapy-naïve advanced PEAC who responded to a combination of pembrolizumab and platinum-containing chemotherapy. The number of PEAC cases is small, and no clinical trials have been conducted to determine an optimal chemotherapy regimen. In this case, we showed that pembrolizumab combined with platinum-containing chemotherapy might effectively treat PEAC.
ISSN:2732-7787
2732-7787
DOI:10.21873/cdp.10102